All side effects are absolutely after receiving PharmaBOL 10. Post-cycle therapy for the drug, taking into account that the course lasts no more than 80 days do not actually need. Pharmasib 15. PHARMASIB tab 15 50 Mode of action - anorectic. It inhibits the reuptake of neurotransmitters - serotonin and norepinephrine in the synaptic cleft, potentiates the synergistic interaction of the central noradrenalin- and serotonergic systems.
Reduces appetite and food intake (increases the feeling of fullness), increases thermogenesis (due to the activation mediated by beta3-adrenoceptor), affects the brown adipose tissue. Formed in the body active metabolites (primary and secondary amines), sibutramine significantly superior in their ability to inhibit the reuptake of serotonin and noradrenaline. In in vitro studies also active metabolites block the reuptake of dopamine, but 3-fold weaker than that of 5-HT and noradrenaline. Neither sibutramine or active metabolites do not affect the release of monoamines and MAO activity do not interact with neurotransmitter receptors, including serotonergic, adrenergic, dopaminergic, benzodiazepine and glutamate (NMDA), no anticholinergic and antihistaminic actions. It inhibits capture of 5-HT and platelet function may change trombotsitov.Snizhenie body weight accompanied by increased serum concentrations of HDL cholesterol and lowering of triglyceride, total cholesterol, LDL cholesterol and uric acid.
During treatment, there is a slight rise in blood pressure at rest (1-3 mm Hg) and a moderate increase in pulse rate (3-7 beats. / Min), but in rare cases may be more pronounced changes. In an application with inhibitors of microsomal oxidation increases in heart rate (2.5 beats. / Min) and lengthens the interval QT (9.5 ms) .In 2-year studies in rats and mice at doses, as a result of which the observed total area under the concentration - time (AUCs) for two active metabolites exceeded those achieved by MRDC in 0,5-21 times, increases the incidence of benign testicular interstitial tissue predominantly in male rats. Carcinogenic effects in mice and female rats were found.
Not mutagenic action does not affect fertility. When administered to rats doses, AUCs both active metabolite which is 43 times higher than observed in the employment MRDC, teratogenic effects have been detected. However, in studies conducted in rabbits line Dutch Belted under conditions when AUCs active metabolites of sibutramine was 5 times greater than using MRDC, in the offspring were observed anomaly physical development (change in shape or size of the muzzle, ear, tail, the thickness of bones ).